6 May 2009: NorDiag ASA invites to a breakfast presentation of the first quarter 2009 results on May 13 2009 at 8:00am at Thon Hotel Vika Atrium, Munkedamsveien 45, Oslo.

Please confirm your participation to elin.flo@nordiag.com or by calling +47 970 62 885. Shareholders who wish to receive the quarterly report by mail are requested to send an email regarding this to the same email address.

Representatives from the Company will be CEO Mårten Wigstøl and CFO Tone Kvåle.

The first quarter report and the presentation will be published on NorDiag's homepage www.nordiag.com.

Contact: CFO Tone Kvåle, phone +47 915 19576.

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions, instruments and tests, for use in diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis, MRSA and DNA from stool. Applications for respiratory pathogens and viruses are under development. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The Company has offices and laboratories in Stockholm - Sweden and West Chester (PA) - USA. The group has 36 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. For further information - www.nordiag.com.

Read the notice in Norwegian here